| Rank |
Title |
Year |
PubWeight™‹?› |
|
51
|
Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.
|
2013
|
0.88
|
|
52
|
Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation.
|
2012
|
0.88
|
|
53
|
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
|
2013
|
0.88
|
|
54
|
Everolimus - a new approach in the treatment of renal cell carcinoma.
|
2010
|
0.87
|
|
55
|
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC).
|
2013
|
0.87
|
|
56
|
Personalized treatment for advanced colorectal cancer: KRAS and beyond.
|
2013
|
0.87
|
|
57
|
Latest developments and emerging treatment options in the management of stomach cancer.
|
2011
|
0.87
|
|
58
|
Critical appraisal of the use of regorafenib in the management of colorectal cancer.
|
2013
|
0.87
|
|
59
|
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.
|
2012
|
0.86
|
|
60
|
DNA repair in cancer: emerging targets for personalized therapy.
|
2014
|
0.86
|
|
61
|
Future of bisphosphonates and denosumab for men with advanced prostate cancer.
|
2014
|
0.86
|
|
62
|
Fertility preservation during cancer treatment: clinical guidelines.
|
2014
|
0.86
|
|
63
|
Effects of CXCR4 siRNA/dextran-spermine nanoparticles on CXCR4 expression and serum LDH levels in a mouse model of colorectal cancer metastasis to the liver.
|
2011
|
0.86
|
|
64
|
Optimal management of cancer anorexia-cachexia syndrome.
|
2010
|
0.86
|
|
65
|
Global cancer research initiative.
|
2010
|
0.86
|
|
66
|
Critical appraisal of the potential use of cannabinoids in cancer management.
|
2013
|
0.86
|
|
67
|
Enteric-coated, highly standardized cranberry extract reduces risk of UTIs and urinary symptoms during radiotherapy for prostate carcinoma.
|
2012
|
0.86
|
|
68
|
Prognostic stratification of colorectal cancer patients: current perspectives.
|
2014
|
0.85
|
|
69
|
Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report.
|
2015
|
0.85
|
|
70
|
Emerging role for leucine-rich repeat-containing G-protein-coupled receptors LGR5 and LGR4 in cancer stem cells.
|
2014
|
0.85
|
|
71
|
Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma.
|
2013
|
0.85
|
|
72
|
Interpreting clinical assays for histone deacetylase inhibitors.
|
2011
|
0.85
|
|
73
|
Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.
|
2012
|
0.85
|
|
74
|
Cardiovascular risk during hormonal treatment in patients with prostate cancer.
|
2011
|
0.85
|
|
75
|
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer.
|
2011
|
0.85
|
|
76
|
Effects of Acanthus ebracteatus Vahl on tumor angiogenesis and on tumor growth in nude mice implanted with cervical cancer.
|
2012
|
0.85
|
|
77
|
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.
|
2010
|
0.85
|
|
78
|
Review of advanced catheter technologies in radiation oncology brachytherapy procedures.
|
2015
|
0.85
|
|
79
|
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
|
2016
|
0.85
|
|
80
|
Role of bevacizumab therapy in the management of glioblastoma.
|
2010
|
0.84
|
|
81
|
Gastric cancer in young people under 30 years of age: worse prognosis, or delay in diagnosis?
|
2013
|
0.84
|
|
82
|
Cancer therapy and cardiovascular risk: focus on bevacizumab.
|
2015
|
0.84
|
|
83
|
Interstitial fluid flow in cancer: implications for disease progression and treatment.
|
2014
|
0.84
|
|
84
|
The association of race with timeliness of care and survival among Veterans Affairs health care system patients with late-stage non-small cell lung cancer.
|
2013
|
0.84
|
|
85
|
Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma.
|
2012
|
0.84
|
|
86
|
C-type lectin receptors and RIG-I-like receptors: new points on the oncogenomics map.
|
2012
|
0.84
|
|
87
|
Nodal involvement pattern in resectable lung cancer according to tumor location.
|
2012
|
0.84
|
|
88
|
Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib.
|
2014
|
0.84
|
|
89
|
Colonic polyps: inheritance, susceptibility, risk evaluation, and diagnostic management.
|
2010
|
0.84
|
|
90
|
From antiangiogenesis to hypoxia: current research and future directions.
|
2010
|
0.84
|
|
91
|
Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.
|
2011
|
0.84
|
|
92
|
TGFbeta signaling supports survival and metastasis of endometrial cancer cells.
|
2009
|
0.84
|
|
93
|
Lenalidomide for the treatment of relapsed and refractory multiple myeloma.
|
2012
|
0.84
|
|
94
|
Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.
|
2014
|
0.84
|
|
95
|
Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review.
|
2009
|
0.83
|
|
96
|
Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer.
|
2013
|
0.83
|
|
97
|
Minimizing second cancer risk following radiotherapy: current perspectives.
|
2014
|
0.83
|
|
98
|
Abiraterone in the treatment of metastatic castration-resistant prostate cancer.
|
2014
|
0.83
|
|
99
|
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
|
2014
|
0.83
|
|
100
|
Genetic factors and breast cancer laterality.
|
2014
|
0.83
|